Solventum (NYSE:SOLV – Get Free Report) and NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.
Volatility and Risk
Solventum has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.
Earnings & Valuation
This table compares Solventum and NeuroOne Medical Technologies”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Solventum | $8.32 billion | 1.84 | $1.56 billion | $8.18 | 11.01 |
| NeuroOne Medical Technologies | $12.10 million | 1.10 | -$3.61 million | ($0.95) | -1.54 |
Solventum has higher revenue and earnings than NeuroOne Medical Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 0.2% of Solventum shares are held by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Solventum and NeuroOne Medical Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Solventum | 17.26% | 25.09% | 8.78% |
| NeuroOne Medical Technologies | -71.50% | -128.12% | -86.34% |
Analyst Ratings
This is a breakdown of recent ratings and target prices for Solventum and NeuroOne Medical Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Solventum | 1 | 3 | 8 | 0 | 2.58 |
| NeuroOne Medical Technologies | 1 | 1 | 3 | 0 | 2.40 |
Solventum presently has a consensus target price of $92.80, suggesting a potential upside of 3.04%. NeuroOne Medical Technologies has a consensus target price of $7.33, suggesting a potential upside of 402.28%. Given NeuroOne Medical Technologies’ higher probable upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Solventum.
Summary
Solventum beats NeuroOne Medical Technologies on 10 of the 14 factors compared between the two stocks.
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
